Plain-English translation of NCT06822738 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new device called XEN63—a tiny gel implant placed in the eye to help lower eye pressure in people with glaucoma. The study will compare two different surgical approaches for placing the implant: one through a small opening on the front of the eye, and another through an opening on the side of the eye. Researchers will track safety and how well this treatment works over 12 months.
Glaucoma is a serious eye disease that can lead to blindness, and some patients don't respond well enough to eye drops or conventional surgery. This medication aims to give people with hard-to-treat glaucoma another option to control their eye pressure and preserve their vision.
You likely qualify if…
You likely don't qualify if…
You would have one surgical procedure on Day 1 to implant the gel device in your eye using one of two approaches. After that, you'll visit the clinic regularly for 12 months for eye exams and measurements to check how well the implant is working and to watch for any side effects. The study will monitor your eye pressure and overall eye health throughout this period.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States